Hikal (HIKAL) share price, P/E, ROE & financials

As of 6 Nov 2026, Hikal is loss-making on a trailing 12-month basis, with a net loss of ₹5.00 Cr, so it has no P/E ratio. The share price is ₹219.52, 16% below its 52-week high. Sales fell 5.4% a year over 3 years. Debt is 0.54× equity, and its dividend yield is 0.3%. It is a small-cap company with a market cap of ₹2,707 Cr, ranked 54th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 8.1% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹219.40
Day high: ₹220.98
Day low: ₹215.27
Prev. close: ₹220.90
Volume: 1.7 L

Health check

6 to check

ReturnsBehind
−8.1% over a year, better than 0 of 7 peers.
Price tagLoss-making
Earnings were negative over the last 12 months.
GrowthShrinking
Sales −5.4% a year over 3 years.
ProfitabilityNegative
ROCE -1.1% vs peer median 17.9%.
Balance sheetStretched
Debt 0.54× equity, operating profit doesn’t cover interest, Piotroski 5 of 9.
Red flags3 to check
Loss-making over the last twelve months.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹2,707 Cr, #54 of 154 in its industry by size.

Defensive

Beta 0.53 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹1,851 Cr · profit ₹−5 Cr

Market cap: ₹2,707 Cr; Small cap
P/E: n/a; Industry 28.7
Price to book: 2.31; Peers 4.99
Dividend yield: 0.27%
ROE: −0.4%; Peers 14.7%
ROCE: −1.1%; Peers 17.9%
Debt to equity: 0.54; Debt ₹639 Cr
EPS (TTM): −₹2.74; Face value ₹2
OPM (TTM): 9.1%; Net margin −0.3%
Sales growth: +7.7%; Latest quarter vs a year ago
Profit growth: n/a; Year-ago quarter not reported
Price to sales: 1.46; EV/EBITDA 12.5

Strengths

Positive operating cash flow in each of the last 4 years.

Risks to check

Loss-making over the last twelve months.
Return on equity is low at −0.4%.
Interest coverage of only 2.4×.

Derived automatically from reported figures. Not a recommendation.

About Hikal

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals industries. The company operates in two segments, Pharmaceuticals and Crop Protection. It provides anti-convulsant, anti-inflammatory, analgesic, anti-parasitic, anti-lipemic, anti-histaminic,…

Headquarters: Navi Mumbai
Employees: 2,152
Sector: Healthcare
ISIN: INE475B01022
Website: hikal.com

Price range

52 weeks

₹146.25₹261.00

Today

₹215.27₹220.98

Avg volume (3M): 15.2 L
1-year return: minus 8.1%
From 52-week high: minus 15.9%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
HIKALHikal	219.52	minus 0.62%	2,707	–	2.31	−1.1%	−0.4%	13.5%	−5.4%	–	0.27%	minus 8.1%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
371	316	491	517	400
346	309	443	452	363
25.1	7.2	47.5	64.9	37
6.8%	2.3%	9.7%	12.6%	9.3%
1	1.9	38	47.1	1.8
17.1	14.9	15.5	14.6	14.9
39.4	41.2	41.2	42	42.7
–	–	−38	−47.1	8.9
−30.4	−47	−9.2	8.3	−9.9
26.3%	25.7%	35.9%	−73.5%	25.3%
−22.4	−34.9	−5.9	14.4	−7.4
-1.82	-2.83	-0.48	1.17	-0.60

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −5.4%
ROE: −0.4%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
2,005	1,769	1,844	1,695
–	minus 11.8%	+4.2%	minus 8.0%
1,747	1,502	1,515	1,549
258	267	329	146
12.9%	15.1%	17.8%	8.6%
−3.1	−1.5	2	85.8
40.9	53.2	72.7	60.4
109	118	134	164
0.5	0.6	−0.1	−85.8
105	95.5	124	−78.3
25.6%	27.1%	26.7%	37.7%
78.4	69.6	90.8	−48.8
–	minus 11.2%	+30.5%	minus 153.7%
6.36	5.64	7.36	-3.96

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
24.7	24.7	24.7	24.7
1,109	1,163	1,238	1,174
748	818	765	684
504	482	502	483
2,385	2,487	2,529	2,365
1,378	1,483	1,478	1,434
429	423	131	107
9.1	5.9	10.3	9.9
26.7	26.3	83.5	13.6
543	549	827	801
2,385	2,487	2,529	2,365

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
315	187	280	302
−292	−174	−137	−145
−7.7	−27	−144	−160
15.3	−14	0.3	−3.4
−303	−204	−137	−148
12.7	−17.5	143	154
−12.3	−14.8	−14.8	−12.3

Shareholding pattern

Source: NSE filings

68.8%

promoters

Promoters68.85%
Public31.15%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	68.85%	31.15%	0.00
30 Jun 2026	68.85%	31.15%	0.00
31 Mar 2026	68.85%	31.15%	0.00
31 Dec 2025	68.85%	31.15%	0.00
30 Sep 2025	68.85%	31.15%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you